Peng Leong

CBO at BioAge

Speaker

Dr. Peng Leong is Chief Business Officer at BioAge where he leads efforts to execute strategic transactions that convert prioritized drug targets into a portfolio of therapies for treating diseases of aging. Peng has played a key role in building BioAge’s pipeline, including in-licensing Azelaprag from Amgen, and establishing research collaborations with Lilly and Novartis. Previously, Peng was CBO of Kazia Therapeutics, responsible for strategy and business development, and in-licensed paxalisib currently in Phase III trials for glioblastoma. Across various roles, including at Merck KGaA and DRI Healthcare, Peng has had a leadership role in the acquisition or sale of over US$ 1 billion in pharmaceutical product rights. He started his career in healthcare investment banking at CIBC World Markets and Piper Jaffray, where he was involved in raising more than US$ 1.4 billion for over 20 biotechnology companies. Peng received a PhD in Biochemistry from the University of Toronto and an MBA from University of California, Berkeley.